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Abstract
Effective statin therapy is associated with a marked reduction of cardiovascular events. However, the explanation for full ben-
efits obtained for LDL cholesterol targets by combined lipid-lowering therapy is controversial. Our study compared the effects 
of two equally effective lipid-lowering strategies on markers of cholesterol synthesis and absorption. A prospective, open label, 
randomized, parallel design study, with blinded endpoints, included 116 subjects. We compared the effects of a 12-week treat-
ment with 40 mg rosuvastatin or the combination of 40 mg simvastatin/10 mg ezetimibe on markers of cholesterol absorption 
(campesterol and β-sitosterol), synthesis (desmosterol), and their ratios to cholesterol. Both therapies similarly decreased total 
and LDL cholesterol, triglycerides and apolipoprotein B, and increased apolipoprotein A1 (P < 0.05 vs baseline for all). Simvas-
tatin/ezetimibe increased plasma desmosterol (P = 0.012 vs baseline), and decreased campesterol and β-sitosterol (P < 0.0001 
vs baseline for both), with higher desmosterol (P = 0.007) and lower campesterol and β-sitosterol compared to rosuvastatin, 
(P < 0.0001, for both). In addition, rosuvastatin increased the ratios of these markers to cholesterol (P < 0.002 vs baseline for 
all), whereas simvastatin/ezetimibe significantly decreased the campesterol/cholesterol ratio (P = 0.008 vs baseline) and tripled 
the desmosterol/cholesterol ratio (P < 0.0001 vs baseline). The campesterol/cholesterol and β-sitosterol/cholesterol ratios 
were lower, whereas the desmosterol/cholesterol ratio was higher in patients receiving simvastatin/ezetimibe (P < 0.0001 vs 
rosuvastatin, for all). Pronounced differences in markers of cholesterol absorption and synthesis were observed between two 
equally effective lipid-lowering strategies.
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A recent meta-analysis has shown that marked reduc-
tions in LDL cholesterol with statins are related to a greater 
absolute decrease in major cardiovascular events (1). The 
most appropriate strategies for achieving greater effective-
ness in cholesterol reduction include the use of high doses 
of potent statins or the combination of lipid-lowering drugs 
(2,3). However, depending on the choice of drugs, significant 
differences in cholesterol absorption and synthesis can be 
expected (4,5).
Indeed, reduction in the endogenous synthesis of 
cholesterol by statins can be accompanied by increased 
intestinal sterol absorption (6). On the other hand, ezetimibe, 
an inhibitor of dietary and biliary intestinal cholesterol 
absorption, has been extensively used as a lipid-lowering 
agent, but its role in endogenous cholesterol synthesis is 
less studied, especially when combined with a statin (7).
Differences in the pharmacokinetic properties of statins 
may account for the effectiveness of cholesterol synthesis 
inhibition as well as for the stimuli of cholesterol absorption. 
Ezetimibe has an estimated half-life of approximately 22 
h (8), while simvastatin was reported to have a relatively 
short half-life of less than 3 h (9).
Recently, the phenotype of high absorption and low 
synthesis of cholesterol has been related to increased 
cardiovascular and all-cause mortality (10). On the other 
hand, some additional benefits of statins, including anti-
inflammatory and antithrombotic properties, or improvement 
of endothelial function are related to the lower expression 
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of intermediate compounds of the endogenous cholesterol 
synthesis pathway (11-13).
Therefore, the overall benefit from lipid-lowering therapy 
for cardiovascular disease prevention seems to depend 
on the effective reduction in both endogenous cholesterol 
synthesis and intestinal absorption of sterols. Since sim-
vastatin is a statin with a short half-life and lower affinity 
for hydroxymethylglutaryl-coenzyme A reductase than the 
latest generation of statins (14,15), we hypothesized that this 
statin could be insufficient to counterbalance the stimulus 
of cholesterol synthesis promoted by ezetimibe.
Thus, we compared the effects of two potent and equally 
effective lipid-lowering strategies on markers of cholesterol 
synthesis and absorption.
Material and Methods
Design and study population
We performed a prospective, randomized, open-label 
study, with parallel arms and blinded endpoints. Patients 
were recruited from the outpatient dyslipidemia unit of the 
Universidade Federal de São Paulo. The trial protocol was 
conducted in accordance with the ethical standards of the 
Universidade Federal de São Paulo on human experimen-
tation and approval was obtained from the Universidade 
Federal de São Paulo Ethics Committee. Written informed 
consent was obtained from all subjects prior to inclusion. 
Eligible patients were men and women, 30 to 75 years 
of age, under treatment for primary or secondary preven-
tion of coronary heart disease, who had an indication for 
lipid-lowering therapy according to the National Cholesterol 
Education Program/Adult Treatment Panel III (NCEP/ATP) 
guidelines (16). A total of 116 subjects completed the study 
protocol. Patients with liver, renal or gastrointestinal dis-
ease, malignancies, and uncontrolled metabolic disorders 
that might affect the tolerability or safety of the treatments 
were excluded. Exclusion criteria during the study were low 
adherence (less than 80%) to the lipid-lowering regimen. 
The major characteristics of the study population are listed 
in Table 1. Risk factors were defined by the NCEP/ATP III 
guidelines (16). Before treatment, all patients received nutri-
tion counseling based on the Therapeutic Lifestyle Changes 
of the NCEP/ATP III (16). They were then randomized to 
receive 40 mg rosuvastatin or the combination of 40 mg 
simvastatin plus 10 mg ezetimibe, daily for 12 weeks. Dur-
ing the study, patients were evaluated at 4-week intervals, 
when compliance with study medication was confirmed. The 
patients did not take lipid-lowering agents 4 weeks before 
the beginning of the study.
Study drugs
Rosuvastatin (Crestor®, IPR Pharmaceuticals, Porto 
Rico) and simvastatin/ezetimibe (Zetsim®, Schering-Plough 
Products, Porto Rico) were supplied by AstraZeneca (Brazil) 
and Merck Co. (Brazil), respectively. 
Blood sample collection and assays
Biochemical analyses were performed in samples 
obtained after a 12-h fasting period at baseline and after 
12 weeks of treatment and were processed by a central 
laboratory of the Universidade Federal de São Paulo using 
automated techniques.
Lipids and biochemistry
Serum total cholesterol, HDL cholesterol, and triglycer-
ides were determined by automated methods (Advia 2400, 
Siemens Healthcare Diagnostics, Japan). LDL cholesterol 
was calculated using the Friedewald equation (17). Apolipo-
protein A1, apolipoprotein B, and highly sensitive C-reactive 
protein (hs-CRP) were determined by nephelometry (Array 
360 CE/AL, Beckmann Coulter, Inc., USA). Alanine ami-
notransferase (ALT), aspartate aminotransferase (AST), 
creatinine, and creatine kinase (CK) were assayed by 
automated techniques (Advia 2400, Siemens Healthcare 
Diagnostics).
Markers of sterol absorption and synthesis
For the quantification of β-sitosterol and campesterol 
(markers of sterol absorption), as well as for desmosterol 
(a precursor of endogenous cholesterol synthesis), we 
used ultra-performance liquid chromatography (UPLC) and 
mass spectrometry (MS) as previously reported (18,19). 
Briefly, the method consisted of liquid-liquid extraction 
followed by separation in the UPLC system and detection 
with an atmospheric pressure chemical ionization (APCI) 
ion source mass spectrometer operating on “single ion 
monitoring” for each sterol (β-sitosterol, campesterol, 
and desmosterol). The MS system (Quattro Premier-XE, 
Waters Co., UK) was adjusted to monitor single ions 
formed by an APCI ion source. The sterols were detected 
as their free forms, i.e., non-esterified, with the ions being 
monitored with a mass to charge ratio (m/z) of 367.30 
for desmosterol, 397.25 for β-sitosterol, and 383.60 for 
campesterol. Absolute values of plasma sterol levels were 
reported as mg/dL. As these sterols are transported by 
lipoproteins, absolute values of sterols were corrected 
for total plasma cholesterol and reported as their ratios 
to cholesterol.
Statistical analyses
Numerical data are reported as means ± SEM or me-
dians (interquartile range). Categorical data are reported 
as number (%) and compared by the Pearson chi-square 
test. Continuous variables were tested for distribution of 
normality by the Kolmogorov-Smirnov test. Variables with 
Gaussian distribution were compared between times and 
groups using a general linear model (GLM) - repeated 
measures. When data were not normally distributed, we 
used Mann-Whitney or Wilcoxon tests for comparisons 
between groups and within groups, respectively. Statistical 
significance was set at P < 0.05. All analyses were two-tailed 
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and were carried out using the SPSS 17.0 for Windows 
(SPSS Inc., USA).
Results
Patients
A total of 116 subjects presented >80% adherence to the 
study protocol. The major characteristics of these subjects 
were comparable between groups at baseline (Table 1).
Lipids, apolipoproteins, and other laboratory 
parameters
At baseline, biochemical analyses including lipid profile 
and apolipoproteins did not differ between groups (Table 
2). A 12-week treatment with either 40 mg rosuvastatin or 
40 mg simvastatin/10 mg ezetimibe promoted similar re-
ductions of total and LDL cholesterol, as well as of serum 
triglyceride levels, without changes in HDL cholesterol. Both 
regimens increased serum apolipoprotein A1 and reduced 
serum apolipoprotein B levels without differences between 
treatment arms (Table 2).
Creatinine and glucose did not differ between groups 
along the study. AST, ALT and CK were slightly increased 
after the treatments, but remained within the normal range. 
hs-CRP levels decreased similarly in each treatment group 
(Table 3).
Campesterol, β-sitosterol and desmosterol
At baseline, plasma levels of campesterol, β-sitosterol 
and desmosterol were comparable between groups. Treat-
ment with high-dose rosuvastatin (40 mg) did not change 
the plasma markers of sterol absorption and endogenous 
cholesterol synthesis over a period of 12 weeks (P = NS, 
Wilcoxon test) (Table 4, Figure 1A-C). Conversely, in 
subjects receiving 40 mg simvastatin/10 mg ezetimibe, 
we observed increased cholesterol synthesis, as shown 
by the increase in plasma desmosterol levels (P = 0.012) 
and by the decrease in cholesterol absorption markers (P 
< 0.0001 for both campesterol and β-sitosterol) at the end 
of treatment compared to their baseline levels (Table 4, 
Figure 1A-C). In addition, patients treated with the com-
bination of simvastatin/ezetimibe presented lower plasma 
campesterol and β-sitosterol levels than those receiving 
rosuvastatin (P < 0.0001); these patients also presented 
higher plasma desmosterol levels (P = 0.007) compared 
to rosuvastatin-treated subjects.
The ratios between absorption markers and cholesterol 
(campesterol/cholesterol, β-sitosterol/cholesterol) and be-
tween synthesis markers and cholesterol (desmosterol/
cholesterol) were also comparable between groups at 
baseline (P = NS). Since rosuvastatin reduced total and 
LDL cholesterol levels, the synthesis and absorption ratios 
for cholesterol were all increased over time (P < 0.002 vs 
baseline). Treatment with simvastatin/ezetimibe decreased 
the campesterol/cholesterol ratio (P = 0.008 vs baseline), but 
did not change the β-sitosterol/cholesterol ratio (P = 0.960 
vs baseline), and increased the desmosterol/cholesterol 
ratio (P < 0.0001 vs baseline). In addition, the campesterol/
cholesterol and β-sitosterol/cholesterol ratios were lower 
Table 1. Baseline characteristics of the study population accord-
ing to treatment assignment.
Characteristic Rosuvastatin 
(N = 58)
Simvastatin/ezetimibe 
(N = 58)
Age, years, median (IQ) 59 (53-65) 59 (54-65)
Male gender, N (%) 17 (29.3) 18 (31.0)
Diabetes mellitus, N (%) 12 (20.7) 14 (24.1)
Hypertension, N (%) 46 (79.3) 44 (75.9)
Smoking, N (%) 5 (8.6) 4 (6.9)
Metabolic syndrome, N (%) 35 (60.3) 27(46.6)
Primary prevention, N (%) 47 (81.0) 48 (82.8)
There were no statistical differences between groups (chi-square 
test). IQ = interquartile range. Metabolic syndrome according to 
the National Cholesterol Education Program/Adult Treatment 
Program III (NCEP/ATP III) guidelines (16).
Table 2. Lipid and apolipoprotein parameters of the two groups at 
baseline and at the end of the study.
Parameter Rosuvastatin 
(N = 58)
Simvastatin/ezetimibe 
(N = 58)
P (wg)
Cholesterol
Baseline 250 ± 6 243 ± 6 <0.0001
End of study 144 ± 4 150 ± 6
LDL-C
Baseline 161 ± 5 160 ± 5 <0.0001
End of study 67 ± 3 76 ± 4
HDL-C
Baseline 54 ± 2 52 ± 2 0.38
End of study 53 ± 2 52 ± 2
Triglycerides
Baseline 173 ± 11 152 ± 9 <0.0001
End of study 117 ± 6 110 ± 6
Apo A1
Baseline 150 ± 4 142 ± 3 0.02
End of study 152 ± 4 148 ± 3
Apo B
Baseline 131 ± 4 133 ± 4 <0.0001
End of study 67 ± 2 71 ± 3
Lipids and apolipoproteins are reported as means ± SEM in mg/
dL. LDL-C and HDL-C = low- and high-density lipoprotein choles-
terol, respectively; Apo = apolipoprotein. There were significant 
statistical differences within groups (wg) (general linear model 
with repeated measures test); however, there were no significant 
differences between groups (general linear model with repeated 
measures test).
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and the desmosterol/cholesterol ratio was higher 
in patients receiving simvastatin/ezetimibe than in 
those treated with rosuvastatin (P < 0.0001, for all; 
Table 4, Figure 2A-C).
Discussion
We found important differences between the two 
lipid-lowering regimens in the balance of markers 
of sterol absorption and synthesis, in spite of a 
similar decrease in serum LDL cholesterol levels. 
Combined therapy with simvastatin plus ezetimibe 
reduced the markers of cholesterol absorption and 
promoted an increase in plasma desmosterol lev-
els, suggesting that the inhibition of endogenous 
cholesterol synthesis by simvastatin is not sufficient 
to avert the increased endogenous synthesis fol-
lowing the blockade of cholesterol absorption by 
ezetimibe. Conversely, treatment with rosuvas-
tatin resulted in a similar decrease in cholesterol 
levels without changes in absolute campesterol, 
β-sitosterol or desmosterol values. However, due 
to the higher degree of cholesterol synthesis inhibi-
tion observed with potent statins alone, the ratios 
between markers of absorption and synthesis and 
cholesterol differed between treatment groups, 
showing exacerbation of the effect of ezetimibe 
increasing endogenous cholesterol synthesis and 
attenuating the expected inhibition of cholesterol 
absorption when used in combination with simvas-
tatin. The reduction in LDL cholesterol observed 
with lipid-lowering agents per se is a stimulus for 
the increase in cholesterol synthesis, regardless 
of the mechanism by which cholesterol is reduced. 
Therefore, when combining a statin with a short 
half-life with an inhibitor of cholesterol absorption with a 
long half-life, we can expect a more pronounced increase 
in cholesterol synthesis markers. Conversely, if a potent 
statin with a long half-life is used alone, a more prominent 
inhibition of cholesterol synthesis can be expected. 
Interestingly, the effects on intestinal absorption markers 
may differ among statins. The maximal doses of atorvastatin 
and rosuvastatin were compared in a study in which the 
authors found a modest absolute decrease in campesterol 
and sitosterol levels with rosuvastatin, and an increase in 
these cholesterol absorption markers with atorvastatin (5). 
The authors postulated an interaction between ABCG5/G8 
transporters and atorvastatin to explain their findings (20). 
Other factors, such as the presence of diabetes, have been 
reported to modify the magnitude of cholesterol synthesis 
inhibition following lipid-lowering therapies (21). 
The relationship between phytosterols and the severity 
of coronary disease was described in the Ludwigshafen 
Risk and Cardiovascular Health (LURIC) study (22), which 
reported data for 2440 individuals in whom coronary angio-
grams and sterol levels were evaluated. The phenotype of 
low cholesterol synthesis combined with high cholesterol 
absorption showed an association with severity of coronary 
disease. In agreement with these findings, the Framingham 
Offspring Study also showed that the low-synthesis and 
high-absorption phenotypes were independent predictors 
of cardiovascular disease (23). In addition, these markers 
of absorption and synthesis are also related to HDL cho-
lesterol concentrations (24). 
Phytosterolemia is a rare genetic disorder characterized 
by a substantial increase in plasma levels of plant sterols 
and premature atherosclerosis (25,26). However, the role 
of modest increases in plasma phytosterol levels in the risk 
for coronary disease is controversial (22,27-30).
Reduction of sterol absorption can prevent the increase 
in cholesterol and plasma plant sterol levels. However, the 
results of our study suggest the need for an effective statin 
to avoid the increase in endogenous cholesterol synthesis 
by the inhibition of cholesterol absorption.
In our study, all patients received nutrition counseling 
Table 3. Laboratory parameters by groups at baseline and at the end of 
the study.
Parameter Rosuvastatin 
(N = 58)
Simvastatin/ezetimibe 
(N = 58)
P (wg)
Creatinine (mg/dL)
Baseline 0.93 ± 0.03 0.92 ± 0.03 0.99
End of study 0.91 ± 0.03 0.94 ± 0.03
AST (IU/L) 
Baseline 22 (19-25) 22 (19-25) 0.001R
End of study 25 (20-32) 24 (21-29)
ALT (IU/L)
Baseline 20 (16-25) 21 (17-30) 0.001R
End of study 23 (17-37) 27 (19-32) <0.0001S/E
CK (IU/L)
Baseline 104 (84-159) 127 (81-167) <0.0001R
End of study 135 (106-204) 118 (95-193) 0.02S/E
hs-CRP (mg/L)
Baseline 2.7 (1.2-5.4) 2.7 (1.6-5.4) <0.0001R
End of study 1.5 (0.9-3.5) 1.6 (0.7-3.2) <0.0001S/E
Glucose
Baseline 97 (88-110) 97 (86-107) 0.67R
End of study 97 (90-105) 97 (89-110) 0.09S/E
AST = aspartate aminotransferase; ALT = alanine aminotransferase; CK = 
creatine kinase; hs-CRP = highly sensitive C-reactive protein. Creatinine is 
reported as means ± SEM and was analyzed by the general linear model 
with repeated measures. AST, ALT, CK, hs-CRP, and glucose are report-
ed as median and interquartile range and were not normally distributed. 
They were analyzed by the Wilcoxon test (for within-group comparisons) 
or the Mann-Whitney test (for between-group comparisons). There were 
significant statistical differences within groups (wg); however, there were 
no significant differences between groups. RComparisons for rosuvastatin 
between visits; S/Ecomparisons for simvastatin/ezetimibe between visits. 
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according to NCEP III guidelines (16). A novel mechanism 
for the reduction of intestinal sterol absorption following the 
intake of plant sterols has been recently described. Inter-
estingly, despite the competition between cholesterol and 
Figure 1. Box-plots (median, 25th and 75th percentiles) for plasma levels of campesterol (A), β-sitosterol (B), and desmosterol (C) at baseline 
and at the end of the study according to treatment. Baseline values were comparable between groups. Rosuvastatin did not modify these 
parameters over time. Subjects treated with simvastatin/ezetimibe presented a reduction of plasma levels of campesterol and β-sitosterol (P 
< 0.0001 vs baseline for both, Wilcoxon test), and an increase of desmosterol (P = 0.012 vs baseline, Wilcoxon test). Plasma campesterol 
and β-sitosterol levels were lower at the end of the study (P < 0.0001 for both, Mann-Whitney test) in subjects receiving simvastatin/ezetimibe 
compared to individuals receiving rosuvastatin, whereas desmosterol levels were higher (P = 0.007, Mann-Whitney test).
Table 4. Markers of cholesterol absorption and synthesis and their ratios to cholesterol by groups at 
baseline and at the end of the study.
Parameter Rosuvastatin Simvastatin/ezetimibe P (bg) P (wg)
Campesterol (mg/dL)
Baseline
Absolute 0.97 (0.57-1.48) 0.89 (0.53-1.51) 0.732 0.263R
Ratio to cholesterol 0.0037 (0.0024-0.0060) 0.0035 (0.0024-0.0070) 0.808 <0.0001R
End of study
Absolute 0.96 (0.76-1.48) 0.40 (0.29-0.57) <0.0001 <0.0001S/E
Ratio to cholesterol 0.0072 (0.0053-0.0093) 0.0028 (0.0019-0.0040) <0.0001 0.008S/E
ß-sitosterol (mg/dL)
Baseline
Absolute 0.66 (0.42-1.00) 0.61 (0.40-1.06) 0.910 0.382R
Ratio to cholesterol 0.0027 (0.0018-0.0039) 0.0029 (0.0016-0.0043) 0.791 <0.0001R
End of study
Absolute 0.72 (0.51-0.99) 0.40 (0.26-0.58) <0.0001 <0.0001S/E
Ratio to cholesterol 0.0050 (0.0036-0.0066) 0.0030 (0.0018-0.0040) <0.0001 0.960S/E
Desmosterol (mg/dL)
Baseline
Absolute 0.39 (0.15-0.85) 0.33 (0.14-1.02) 0.987 0.972R
Ratio to cholesterol 0.0014 (0.0006-0.0031) 0.00 14 (0.0005-0.0034) 0.886 0.001R
End of study
Absolute 0.43 (0.22-0.72) 0.62 (0.45-1.02) 0.007 0.012S/E
Ratio to cholesterol 0.0033 (0.0017-0.0051) 0.0046 (0.0027-0.0071) 0.010 <0.0001S/E
Data as reported as medians (25th-75th percentiles). RComparisons for rosuvastatin between visits; 
S/Ecomparisons for simvastatin/ezetimibe between visits. There were significant statistical differences 
both between (bg; Mann-Whitney test) and within groups (wg; Wilcoxon test).
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plant sterols for incorporation into micelles, β-sitosterol was 
reported to reduce the expression of the Niemann-PickC1-
like 1 (NPC1L1) transporter (31). Therefore, in our study, a 
less pronounced increase in phytosterol levels may have 
been influenced by the adherence of these subjects to the 
diet in both arms.
Recently, a meta-analysis of data from 170,000 subjects 
in 26 randomized studies confirmed the benefit and safety 
of LDL cholesterol lowering using statins, and suggested 
that the reduction of 2-3 mM would reduce major cardiovas-
cular events by about 40-50% (1). On the other hand, the 
benefits of LDL cholesterol lowering using other strategies 
seem less clear (32-34).
Our results showed that two highly effective lipid-lower-
ing strategies induced a similar reduction of LDL cholesterol 
levels. However, substantial differences were found in the 
metabolism of sterols. Since differences in cholesterol 
homeostasis characterized by the balance between sterol 
absorption and synthesis are related to the severity of coro-
nary disease, these differences may explain the unexpected 
findings in recent clinical trials. Further studies addressing 
cardiovascular events are needed to assess the impact of 
such differences on sterol metabolism.
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